USPTO serial 90149626
INSIGNIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 16, 2024
- Examiner
- BAKER, JORDAN A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INSIGNIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joi A. White
Joi A. White Carr & Ferrell LLP411 Borel Avenue, Suite 603San Mateo, CA 94402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science, photography, agriculture, horticulture and forestry, except fungicides, herbicides, insecticides, and parasiticides; reagents and reactants for non-medical purposes; enzymes for industrial or scientific purposes; nucleic acid for other than medical and veterinary purposes; nucleic recombinant acids for other than medical and veterinary purposes; acids, namely, inorganic acids for industrial purposes; DNA and RNA polymerase; chemicals used in food processing and screening; chemicals used in environmental monitoring | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations and substances for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and/or immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and/or analysis of epigenetic alterations, analysis of response to therapy; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use; chemical preparations containing enzymes for medical purposes; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes for the diagnosis of diseases or detection or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune-suppression and/or immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and/or analysis of epigenetic alterations, analysis of response to therapy; enzymes for pharmaceutical, veterinary and medical purposes; medical kits containing medical and/or pharmaceutical preparations and associated detection reagents for the diagnosis of diseases, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; clinical diagnostics for medical or veterinary use; biological chemical test kits comprised of reagents and assays for medical laboratory use in analysis that test for the presence of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders | ACTIVE | — |
| 010 | Surgical apparatus and instruments; medical and veterinary apparatus and instruments for use in analyzing and assessing the presence of active bacterial infections and analyzing and assessing Antimicrobial Resistance (AMR) status; diagnostic testing apparatus and instruments for medical purposes, namely, for use in analyzing and assessing the presence of active bacterial infections and analyzing and assessing Antimicrobial Resistance (AMR) status; diagnostic testing kits containing diagnostic testing apparatus for use in analyzing and assessing the presence of active bacterial infections and analyzing and assessing Antimicrobial Resistance (AMR) status; point of care medical devices for use in analyzing and assessing the presence of active bacterial infections and analyzing and assessing Antimicrobial Resistance (AMR) status; screening kits consisting of medical screening and testing apparatus for the diagnosis of disease, detection and/or identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolic expression, inflammation, and immune suppression and/or immune disorders for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and/or analysis of epigenetic alterations, analysis of response to therapy; all of the foregoing excluding heart pacemakers and stethoscopes and orthopedic implants and excluding apparatus, instruments and devices for use with orthopedic surgery and excluding surgical staplers and accessories therefor | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, in the field of DNA analysis services for scientific research analysis, and scientific research consulting in the field of genetics; scientific genetic research; genetic engineering services for scientific purposes; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; chemistry services, namely, chemistry research services; research relating to chemistry; scientific research relating to chemistry; research in the field of chemistry; laboratory analysis in the field of chemistry; development of medical diagnostic apparatus; design of medical diagnostic apparatus; research relating to molecular sciences; analysis of data generated by scientific and medical experiments and tests; biological, bacteriological, chemical, biochemical, DNA, RNA, protein, polynucleic acid and molecular analysis and evaluation services for scientific purposes and medical research purposes; DNA and RNA and polynucleic acid and protein sequencing, analysis and evaluation services, for scientific purposes and medical research purposes; genome sequencing services and the analysis and evaluation of data resulting therefrom, for scientific purposes and medical research purposes; scientific analysis and the provision of reports in conjunction therewith relating to scientific and medical experiments, relating to the results of scientific and medical experiments and tests, relating to the analysis and evaluation of scientific and medical data, and relating to data generated by scientific and medical experiments and tests; scientific and medical research and development services in the field of medical research and genetics; custom design and development of biochemical assays | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks owned by SpeeDx Pty Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named INSIGNIA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 16, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 11, 2024 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 22, 2024 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Feb 20, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| Jan 23, 2024 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 19, 2024 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jan 2, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 2, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 13, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 19, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 12, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Sep 5, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Aug 21, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 21, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 21, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 21, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 19, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 18, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 18, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 31, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 31, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 31, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 13, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 12, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 8, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 8, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 27, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jul 22, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 20, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jul 22, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 22, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 22, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 21, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 21, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 21, 2021 | ALIE | ASSIGNED TO LIE | — |
| Jul 6, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 5, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 8, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 3, 2020 | NWAP | NEW APPLICATION ENTERED | — |